1. Home
  2. RBOT vs CTSO Comparison

RBOT vs CTSO Comparison

Compare RBOT & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vicarious Surgical Inc.

RBOT

Vicarious Surgical Inc.

HOLD

Current Price

$3.05

Market Cap

17.0M

Sector

Health Care

ML Signal

HOLD

Logo Cytosorbents Corporation

CTSO

Cytosorbents Corporation

HOLD

Current Price

$0.72

Market Cap

49.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RBOT
CTSO
Founded
2014
1997
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
17.0M
49.7M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
RBOT
CTSO
Price
$3.05
$0.72
Analyst Decision
Hold
Buy
Analyst Count
1
2
Target Price
$7.00
$5.38
AVG Volume (30 Days)
152.1K
126.1K
Earning Date
11-12-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$36,979,520.00
Revenue This Year
N/A
$9.51
Revenue Next Year
N/A
$24.40
P/E Ratio
N/A
N/A
Revenue Growth
N/A
23.89
52 Week Low
$2.44
$0.60
52 Week High
$19.00
$1.61

Technical Indicators

Market Signals
Indicator
RBOT
CTSO
Relative Strength Index (RSI) 39.85 46.64
Support Level $2.54 $0.70
Resistance Level $3.66 $0.85
Average True Range (ATR) 0.38 0.07
MACD 0.11 0.01
Stochastic Oscillator 44.26 52.04

Price Performance

Historical Comparison
RBOT
CTSO

About RBOT Vicarious Surgical Inc.

Vicarious Surgical Inc designs a surgical robot that enables surgeons to perform minimally invasive surgery with 3D visualization and accurate control. Its Vicarious Surgical Robotic System is designed with a focus on abdominal access and visualization through a single port. The company has following segment: Research and development, Sales and marketing, General and administrative.

About CTSO Cytosorbents Corporation

CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.

Share on Social Networks: